David H. Henry, M.D.

faculty photo
Clinical Professor of Medicine
Department: Medicine

Contact information
Penn Hematology/Oncology
Abramson Cancer Center
Pennsylvania Hospital, Farm Journal Building
230 West Washington Square
Philadelphia, PA 19106
Office: 215-829-6088
Fax: 215-829-6104
Education:
B.A.
Princeton University, 1970.
M.D.
University of Pennsylvania School of Medicine, 1975.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Henry, DH., Maki RG: Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clin Canc Res 28(12): 2485-2487, Jun 13 2022.

Henry DH: Quantitative Nodal Burden and Mortality across Solid Cancers. PracticeUpdate April 2022.

Jacobson, D., Cadieux, B., Higano, CS., Henry, DH., Bachmann, BA., Rehn, M., Stopeck, AT., Saad, H: Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach. J Bone Oncol 34: 100423, Mar 17 2022.

Prasad Siobhan, Barfejani Arnavaz, Henry David, FEVER STATUS AND : ANTIBIOTIC DELIVERY IN THE NEUTROPENIC PATIENT Supportive Care in Cancer MASCC/ISOO Annual Meeting Page: S1–S207, 2022.

Jacobson, D., Cadieux, B., Higano, CS., Henry, DH., Bachmann, BA., Rehn, M., Stopeck, AT., Saad, H: Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach. Journal of Bone Oncology 2022.

Henry D, Barfejani AH, Prasad S: A commentary on: 2021 Top Story in Oncology: Surgically Preventing HPV-Related Anal Cancer in HIV-Infected Individuals. PracticeUpdate December 2021.

Makharadze, T, Boccia, R, Krupa, A, Blackman, N, Henry, DH, Gilreath, JA: Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD). Am J Hematol 96(12): 1639-1646, Dec 1 2021.

Henry,D: A commentary on: Cemiplimab With Platinum Doublet Chemo as First-Line for Advanced NSCLC. PracticeUpdate website. PracticeUpdate October 2021.

Henry D: A commentary on: Trastuzumab Deruxtecan for HER2-Mutated Metastatic NSCLC. PracticeUpdate October 2021.

Henry D: A commentary on: PD-L1b Inhibitors for Nsq-NSCLC. PracticeUpdate October 2021.

back to top
Last updated: 11/14/2022
The Trustees of the University of Pennsylvania